Skip to main content
Clinical Trials/IRCT201202014010N7
IRCT201202014010N7CompletedPhase 2

Evaluating the effect of Resveratrol supplement on lipid profile, hepatic enzymes, inflammatory factors, and hepatic fibrosis in patients with Nonalcoholic Fatty Liver Disease (NAFLD)

ational Nutrition and Food Technology Research Institute0 sites50 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 65 years (—)
Sex
All

Inclusion Criteria

  • Age 18 and older; Evidence of nonalcoholic steatohepatitis with steatosis grade higher or equal to 1 in ultrasonography; No history of Alcohol consumption or consuming less than 10 grams alcohol per day in women and less than 20 grams per day in men; Absence of other liver disorders, malignancies, cardiovascular, respiratory, and kidney disorders; Absence of pregnancy or lactation; Absence of taking any medications in the past three months; Absence of weight loss in the recent three months; Absence of endocrine and metabolism disorders. Exclusion criteria: Weight loss more than 10% of baseline body weight during the intervention period. Pregnancy; Disliking to continue the study.

Exclusion Criteria

  • Not provided

Investigators

Sponsor
ational Nutrition and Food Technology Research Institute

Similar Trials